Suggested remit: To appraise the clinical and cost effectiveness of teplizumab within its marketing authorisation for delaying the onset of type 1 diabetes in people aged 8 and over at risk of developing the condition.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6259
Provisional Schedule
- Expected publication:
- 26 November 2025
Project Team
- Project lead
- Jen Upton
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Sanofi (Teplizumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Breakthrough T1D
- Diabetes UK
- Professional groups
- British Society for Paediatric Endocrinology & Diabetes
- Royal College of Physicians
- UK Clinical Pharmacy Association
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Government
- NHS Wales Joint Commissioning Committee
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 August 2025 | At the appraisal committee meeting in May 2025, the committee was not able to recommend teplizumab because more evidence is needed. The appraisal has had a short pause while NICE worked to identify how additional information can be obtained, and is now proceeding with a draft guidance consultation. A second committee discussion has been scheduled. |
| 06 May 2025 | Committee meeting |
| 06 May 2025 | Declaration of interests |
| 24 September 2024 | Invitation to participate |
| 03 July 2024 - 31 July 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6259 |
| 03 July 2024 | In progress. Scoping commencing |
| 23 February 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late September 2024 when we will write to you about how you can get involved. |
| 14 March 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual